Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jenny Guerre

Neurology Shreveport, LA Medical Doctor

NPI 1063559789 CMS profile 93839

1541 Kings Hwy, Shreveport, LA 71103

Open in the dashboard

General payments

$15,254

561 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jenny Guerre of Shreveport, LA is reported in the CMS Open Payments database as having received $15,254 across 561 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 80th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $9,215 168
2024 General $1,844 127
2023 General $1,852 120
2022 General $1,179 72
2021 General $465 26
2020 General $44 2
2019 General $656 46

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jenny Guerre
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Jenny Guerre were reported at $9,215. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Jenny Guerre Neurology median Middle half National median
2019 $656 $474 $118–$2,177 $163
2020 $44 $367 $82–$2,309 $114
2021 $465 $438 $104–$2,547 $132
2022 $1,179 $442 $103–$2,388 $149
2023 $1,852 $464 $119–$2,312 $160
2024 $1,844 $468 $119–$2,323 $164
2025 $9,215 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Argenx US, Inc. $7,433 27 payments
  2. AbbVie, Inc. $1,139 94 payments
  3. ACADIA Pharmaceuticals Inc $1,102 127 payments
  4. Neurocrine Biosciences, Inc. $613 58 payments
  5. Biogen, Inc. $423 22 payments
  6. Amgen Inc. $423 20 payments
  7. EMD Serono, Inc. $364 17 payments
  8. Novartis Pharmaceuticals Corporation $339 20 payments
  9. Alexion Pharmaceuticals, Inc. $335 15 payments
  10. Genentech USA, Inc. $298 15 payments
  11. Other $2,785 146 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $8,421 551 payments
  2. Consulting Fee $5,500 1 payment
  3. Travel and Lodging $1,264 6 payments
  4. Education $57 2 payments
  5. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $12 1 payment
Products named General payments · program years 2019–2025
  1. VYVGART Hytrulo $7,310 25 payments
  2. NUPLAZID $826 105 payments
  3. INGREZZA $571 56 payments
  4. UBRELVY $530 42 payments
  5. QULIPTA $522 39 payments
  6. BOTOX $507 48 payments
  7. VYVGART $367 12 payments
  8. KESIMPTA $267 16 payments
  9. UPLIZNA $257 12 payments
  10. NURTEC ODT $255 16 payments
  11. Other $4,778 265 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 27 drugs

Part D claims

718

Median for Neurology: 833

Drug cost

$1,725,960

Median for Neurology: $202,670

Branded share of claims

31.6%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Evrysdi Risdiplam Brand 20 $527,503
Gammaked Immune Globul G/Gly/Iga Avg 46 Brand 17 $290,659
Radicava Ors Edaravone Brand 16 $222,925
Ingrezza Valbenazine Tosylate Brand 39 $207,413
Octagam Immun Globg(Igg)/Malt/Iga Ov50 Brand 12 $175,110
Privigen Immun Glob G(Igg)/Pro/Iga 0-50 Brand 14 $148,024
Gamunex-C Immune Globul G/Gly/Iga Avg 46 Brand 11 $120,874
Aptiom Eslicarbazepine Acetate Brand 11 $13,143
Pyridostigmine Bromide Er Pyridostigmine Bromide Brand 21 $6,970
Pyridostigmine Bromide Generic 54 $3,920

The 10 drugs with the highest cost, of 27 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 33 billing codes

Paid by Medicare

$17,662

Medicare's payments for the services billed

Medicare patients

109

Average age 67

Services billed

354

55 women, 54 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 45%
Diabetes 36%
Depression 28%
Ischemic heart disease 25%
Heart failure 19%
COPD 19%
Atrial fibrillation 15%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 24 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
NUPLAZID
  • ACADIA Pharmaceuticals Inc $200
$200 — —
INGREZZA
  • Neurocrine Biosciences, Inc. $166
$166 39 —
KESIMPTA
  • Novartis Pharmaceuticals Corporation $147
$147 — —
BOTOX
  • AbbVie, Inc. $130
$130 — —
QULIPTA
  • AbbVie, Inc. $95
$95 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 24 in the dashboard with a free account

Records

561 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Louisiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record